ClinicalTrials.gg

Program

CS-121

A development code.

Its studies are mostly in Hypertriglyceridemia, led by CorrectSequence Therapeutics.

Furthest: early phase 1, since Aug 30, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2026 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CorrectSequence Therapeutics22 open or runningearly phase 1since Aug 30, 2025Aug 30, 2025Dec 2026early phase 1 · NCT07176923

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 30, 2025First study: early phase 1 study in Familial hyperchylomicronemia syndromeFirst studyNCT07176923 · 15 planned · China
  2. Jun 15, 2026Early phase 1 study in HypertriglyceridemiaNCT07657780 · 15 planned · China

Ahead

  1. Dec 2026Primary completion: early phase 1 study in Familial hyperchylomicronemia syndromeNCT07176923
  2. Mar 15, 2028Primary completion: early phase 1 study in HypertriglyceridemiaNCT07657780

TargetBeta

APOC3 →read by rule
“A Clinical Study to the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3 for the Treatment of Severe Hypertriglyceridemia in Adults”study text, by rule · the study

Other programs on APOC3

ProgramCompanyFurthest phaseStudies
HRS-7249Jiangsu HengRui Medicinephase 24
FXR0906Fosun Pharmaphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07657780Hypertriglyceridemia · ChinaEarly 1Not yet recruitingMar 15, 202815
NCT07176923Familial hyperchylomicronemia syndrome · ChinaEarly 1RecruitingDec 202615

How it is read

Names in the registry

  • “CS-121”, 2 entries

Codes read as this program: CS121.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.